Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Rule 8.1-Torex Retail-Replace

21 Jun 2005 12:44

Evolution Securities21 June 2005 The 'Rule 8 - Torex Retail PLC' announcement released today at 11.55 under RNS No 8332N has been amended. The paragraph under the Amount bought column relating to the Trade Amendment was omitted. The full amended text is shown below. FORM 8.1 DEALINGS BY OFFERORS, OFFEREE COMPANIES OR THEIR ASSOCIATES FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS (Rules 8.1(a) and (b)(i) of The City Code on Takeovers and Mergers) Name of purchaser/vendor * EVOLUTION SECURITIES LIMITED Company dealt in TOREX RETAIL Relevant security dealt in ORD Name of offeree/offeror with which associated TOREX RETAIL Specify category and nature of associate status # ADVISOR/BROKER - CATEGORY 2 Date of dealing 20 JUNE 2005 DEALINGS + Amount bought Price per unit (currency must be stated)127,350 105.00P 8,000 106.50P300,000 107.00P Trade Amendment from 17/06/05:127,200 at 105.00p now 127,188 at 105.00p Amount sold Price per unit (currency must be stated) 4,642 106.10P 2,950 106.40P373,100 107.00P 1,478 107.10P 3,400 108.00P Resultant total amount and percentage of the same relevant security owned or controlled -10,472 (-0.005%) IS A SUPPLEMENTAL FORM 8 (DERIVATIVE)/FORM 8 (OPTION) ATTACHED? NO Date of disclosure 21 JUNE 2005 Contact name DINA PATEL Telephone number 020 7071 4449 * Specify the owner or controller in addition to the person dealing. The naming of nominees or vehicle companies is insufficient. In the case of disclosure of dealings by fund managers on behalf of discretionary clients, the clients need not be named.# See the definition of "associate" in the Definitions Section of the Code.+ If disclosing dealings/holdings in derivatives or options, please attach Supplemental Form 8 (Derivative) or Supplemental Form 8 (Option), as appropriate. For details of the Code's dealing disclosure requirements, see Rule 8 and itsNotes which can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
29th Jul 20138:45 amRNSTissue Regenix Key Appointment at USA Subsidiary
25th Jul 20134:59 pmRNSHolding(s) in Company
17th Jul 20137:00 amRNSAppointment of Non-Executive Director
10th Jul 20137:00 amRNSAppointment of Non-Executive Director
18th Jun 20137:00 amRNSTissue Regenix advances US commercialisation
14th Jun 201312:43 pmRNSResult of AGM
14th Jun 20137:00 amRNSPresentation of dCELL at heart valve event
28th May 20137:00 amRNSAppointment of Business Development Manager
14th May 20133:47 pmRNSAnnual Report and Notice of AGM
13th May 20137:00 amRNSPreliminary results for the year ended 31 Jan 2013
3rd May 20137:00 amRNSNotice of Results
2nd May 20137:00 amRNSResults of dCELL Dermis trial
29th Apr 20137:00 amRNSChange of Nominated Adviser and Broker
16th Apr 20137:00 amRNSApproval for start of clinical research trial
2nd Apr 20137:00 amRNSTissue Regenix makes appointment to US subsidiary
11th Mar 20137:00 amRNSDirector Change
15th Feb 20132:38 pmRNSHolding(s) in Company
14th Feb 20137:00 amRNSSuccessful safety study of dCELL® Meniscus
11th Feb 20132:57 pmRNSDirectorate Change
9th Jan 20137:15 amRNSHolding(s) in Company
30th Nov 201211:21 amRNSTissue Regenix board changes
26th Nov 20127:00 amRNSSets up US subsidiary
19th Nov 20127:00 amRNSAdds new patent global licence portfolio
4th Oct 20127:00 amRNSInterim data from clinical trial of dCELL® Dermis
4th Oct 20127:00 amRNSHalf Yearly Report
1st Oct 201210:57 amRNSTissue Regenix - senior development appointment
28th Sep 20123:30 pmRNSNotice of Results
7th Sep 20127:00 amRNSdCELL(R) vascular patch is safe and effective
2nd Aug 20122:31 pmRNSTissue Regenix makes appointment to Cardiac team
31st Jul 20123:02 pmRNSDirector/PDMR Shareholding
19th Jun 20122:39 pmRNSHolding(s) in Company
14th Jun 20127:00 amRNSResearch Update
11th Jun 201212:35 pmRNSResult of AGM
25th May 20127:00 amRNSExpands scope of development activities with NHSBT
10th May 20127:00 amRNSFinal Results
19th Apr 20121:49 pmRNSPoster shown at SAWC
16th Apr 20123:18 pmRNSNotice of Results
7th Feb 20124:00 pmRNSIssue of Equity and Total Voting Rights
11th Jan 201211:36 amRNSHolding(s) in Company
6th Jan 20125:05 pmRNSHolding(s) in Company
3rd Jan 20125:45 pmRNSHolding(s) in Company
3rd Jan 20125:43 pmRNSHolding(s) in Company
3rd Jan 20128:49 amRNSHolding(s) in Company
28th Dec 201112:00 pmRNSResult of General Meeting
8th Dec 201112:53 pmRNSIssue of Equity
25th Nov 20112:23 pmRNSUniversity Partner wins Queen's Anniversary Prize
4th Nov 20112:16 pmRNSHolding(s) in Company
14th Oct 20112:33 pmRNSHolding(s) in Company
10th Oct 20117:00 amRNSHalf Yearly Report
26th Jul 201111:04 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.